If you have been reading about Phase 3 trial and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Precautions and contraindications == Administration of tylosin should be avoided in animals with a known hypersensitivity to the product, or to other macrolides. Oral administration can result in diarrhoea and gastrointestinal disturbance. This is particularly true of horses, such that it can be fatal. Tylosin also has a foul taste that is difficult to disguise. The injectable formulations of tylosin can cause pain, inflammation, and itchiness around the injection site. Since tylosin has a relatively poor spectrum of activity against Gram-negative organisms, it may not be a sensible therapeutic choice in the treatment of infections caused by unknown, potentially unsusceptible organisms.
Clematis ispahanica Bioss Clematis × jackmanii T.Moore – Jackman's clematis Clematis koreana Kom. – Korean clematis Clematis lanuginosa Lindl. & Paxton Clematis lasiantha Nutt. – pipestem clematis Clematis leptophylla (F.Muell. ex Benth.) H.Eichler Clematis ligusticifolia Nutt. – western white clematis, hierba de chivo Clematis linearifolia Steud. Clematis macropetala Ledeb. – downy clematis Clematis mandshurica Clematis marmoraria Sneddon – New Zealand dwarf clematis Clematis microphylla DC. – small-leaved clematis Clematis montana Buch.-Ham. ex DC. – anemone clematis Clematis morefieldii Kral – Huntsville vasevine Clematis napaulensis DC. Clematis occidentalis (Hornem.) DC. – western blue virginsbower Clematis ochroleuca Ait. – curlyheads Clematis orientalis L. – Chinese clematis Clematis palmeri Rose – Palmer clematis Clematis paniculata J.F.Gmel. – puawhananga Clematis patens C.Morren & Decne. Clematis pauciflora Nutt. – ropevine clematis Clematis pickeringii A.Gray Clematis pitcheri Torr. & A.Gray – bluebill Clematis pubescens Hügel ex Endl. – common clematis Clematis recta L. – ground clematis Clematis reticulata Walter – netleaf leather flower Clematis rhodocarpa Rose Clematis smilacifolia Wall. Clematis socialis Kral – Alabama leather flower Clematis stans Siebold & Zucc. – kusabotan Clematis tangutica (Maxim.) Korsh. – golden clematis Clematis terniflora DC. – sweet autumn clematis Clematis texensis Buckley – scarlet leather flower Clematis urophylla Clematis versicolor – manycolored leather flower Clematis verticillaris – purple virgins bower Clematis viorna L.
Impact factor data ... have a strong influence on the scientific community, affecting decisions on where to publish, whom to promote or hire, the success of grant applications, and even salary bonuses. More targeted research has begun to provide firm evidence of how deeply the impact factor is embedded within formal and informal research assessment processes. A review in 2019 studied how often the JIF featured in documents related to the review, promotion, and tenure of scientists in US and Canadian universities. It concluded that 40% of universities focused on academic research specifically mentioned the JIF as part of such review, promotion, and tenure processes. A 2017 study of how researchers in the life sciences behave concluded that "everyday decision-making practices as highly governed by pressures to publish in high-impact journals." It has been argued that the deeply embedded nature of such indicators not only affects research assessment, but the more fundamental issue of what research is actually undertaken: "Given the current ways of evaluation and valuing research, risky, lengthy, and unorthodox project rarely take center stage."
These include the taste receptors, various cells of the gastric glands, centroacinar cells of the pancreas, enterocytes lining the intestinal epithelium, and microfold cells also known as mucosal cells, mainly found in gut-associated lymphoid tissue of the small intestine. Some parts of the digestive system are also part of the excretory system, including the large intestine.
Sources: en.wikipedia.org
The affinity of metal ions for ligands is described by a stability constant, also called the formation constant, and is represented by the symbol Kf. It is the equilibrium constant for its assembly from the constituent metal and ligands, and can be calculated accordingly, as in the following example for a simple case:
An enzyme inhibitor is characterised by its dissociation constant Ki, the concentration at which the inhibitor half occupies the enzyme. In non-competitive inhibition the inhibitor can also bind to the enzyme-substrate complex, and the presence of bound substrate can change the affinity of the inhibitor for the enzyme, resulting in a second dissociation constant Ki'. Hence Ki and Ki' are the dissociation constants of the inhibitor for the enzyme and to the enzyme-substrate complex, respectively. The enzyme-inhibitor constant Ki can be measured directly by various methods; one especially accurate method is isothermal titration calorimetry, in which the inhibitor is titrated into a solution of enzyme and the heat released or absorbed is measured. However, the other dissociation constant Ki' is difficult to measure directly, since the enzyme-substrate complex is short-lived and undergoing a chemical reaction to form the product. Hence, Ki' is usually measured indirectly, by observing the enzyme activity under various substrate and inhibitor concentrations, and fitting the data via nonlinear regression to a modified Michaelis–Menten equation.
The district's borders, which correspond to the former city's borders, are: Victoria Park Avenue (facing the rest of Toronto) to the west, the Rouge River, the Little Rouge Creek and the Scarborough-Pickering Townline (facing Pickering) to the east, Steeles Avenue (facing Markham) to the north, and Lake Ontario to the south. Topographically, the district is dominated by two watersheds, Highland Creek and the Rouge River. Highland Creek lies almost entirely within Scarborough and occupies approximately 70% of its total area. It occupies the western half of Scarborough, while the Rouge River flows through the eastern portion. Both of these rivers flow into Lake Ontario. Due to the location of the Lakeshore CN railway right-of-way, both river deltas are constricted to narrow channels where they flow into the lake. Highland Creek is the most urbanized watershed in Toronto with about 85% of its land use devoted to urban uses. Some sections of the river run through parks and remain in a fairly natural state, while other parts run through industrial or residential districts where the flow is often diverted or channelled. Sections of the creek are marked by deep ravines and valleys, which contain little or no urban development. The deep valley the creek cuts in its bottom sections remains primarily parkland, with little or no development taking place within the valley. Conversely, the Rouge River valley has parts which are still in a natural, wooded state.
February 18: Law amending the Civil Code texts related to the legal capacity of married women. March 21: Order from the Ministry of Labor making binding the collective agreement for the wholesale wine and spirits trade in the Libourne district: within this agreement, wages differ notably based on the employee's gender (women receiving a "female wage," systematically lower than their male counterparts) — "this example of a collective agreement shows that the notion of 'female wage,' significantly lower than that of men, is embedded in the legal system of the time." April 9: Law regarding the promotion of female assistant inspectors in public welfare to the rank of inspector. November 12: Decree-law aimed at encouraging birth rates. 1939
=== 3. Cementum === In periodontal breakdown associated with attachment loss, previously covered cementum surfaces become exposed to the oral environment. As periodontal ligament fiber insertions are destroyed, cementum loses its functional connective tissue anchorage, leaving the root surface vulnerable and biologically altered.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.